Tarsus Pharmaceuticals Q2 EPS $(0.48) Misses $(0.39) Estimate, Sales $102.660M Beat $95.682M Estimate
Benzinga Newsdesk 1 year ago
EarningsEarnings BeatsEarnings MissesNews
Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.39) by 23.08 percent. This is a 45.45 percent increase over losses of $(0.88) per
Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.39) by 23.08 percent. This is a 45.45 percent increase over losses of $(0.88) per share from the same period last year. The company reported quarterly sales of $102.660 million which beat the analyst consensus estimate of $95.682 million by 7.29 percent. This is a 151.54 percent increase over sales of $40.813 million the same period last year.